• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Viatris Inc (NQ: VTRS )

    10.32 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 10.32
    Bid (Size) 10.24 (2)
    Ask (Size) 10.38 (2)
    Prev. Close 10.32
    Today's Range 10.32 - 10.32
    52wk Range 8.740 - 13.62
    Shares Outstanding 1,212,301,241
    Dividend Yield 4.65%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    S&P 500 Four Under Five
    The S&P 500's strong first half, with gains exceeding 15%, has pushed its valuation even higher. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Peering Into Viatris's Recent Short Interest
    Via Benzinga

    Performance

    YTD
    -9.39%
    -9.39%
    1 Month
    -1.43%
    -1.43%
    3 Month
    -12.17%
    -12.17%
    6 Month
    -11.87%
    -11.87%
    1 Year
    +3.93%
    +3.93%

    More News

    Read More
    Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
    Via Benzinga
    Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Looking Into Viatris's Recent Short Interest
    Via Benzinga
    (VTRS) - Analyzing Viatris's Short Interest
    Via Benzinga
    VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    BTIG Research Predicts Over 118% Rally for These 3 Stocks
    Via InvestorPlace
    Steady Returns Ahead: 3 Dividend Stocks for Stable Income in Q2
    Via InvestorPlace
    Is Viatris a Great Dividend Stock or Just a Value Trap?
    Via The Motley Fool
    2 Dirt Cheap Dividend Stocks to Buy and Hold
    Via The Motley Fool
    Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
    From Scott+Scott Attorneys at Law and Hedin Hall LLP
    Via Business Wire
    Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments
    Via Benzinga
    Earnings Scheduled For February 28, 2024
    Via Benzinga
    3 Overextended Stocks That Need to Slash Their Dividends ASAP
    Via InvestorPlace
    3 Bargain Stocks to Snatch Up Before They Bounce Back
    Via InvestorPlace
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    The Terrible Ten
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    The Terrible Ten
    Via Talk Markets
    These 9 Stocks Are Running To Start 2024
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Are defensive sectors ready to outshine growth in 2024?
    Via MarketBeat
    Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.